Eosinophilic esophagitis (EoE) is increasing in western nations. Symptoms in infants and young children include feeding difficulties, failure to thrive, and gastroesophageal reflux. School-aged children may present with vomiting, abdominal…
Eosinophilic esophagitis (EoE) is an increasingly recognized immune antigen-mediated esophageal disease found in both children and adults. It is defined as a clinicopathologic disease characterized by symptoms of esophageal dysfunction…
In this article, the epidemiology of eosinophilic esophagitis (EoE) is reviewed. Demographic features and natural history are described, the prevalence and incidence of EoE are highlighted, and risk factors for…
Ikuo Hirano, MD, Editor Eosinophilic esophagitis (EoE) has emerged over the past two decades as an important cause of upper gastrointestinal symptoms in both adults and children. Defined as a…
Gary W. Falk, MD, MS, Editor Eosinophilic esophagitis (EoE) is a disease that was virtually unheard of 20 years ago. Yet, in recent years, there has been an explosive increase…
Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies,…
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn’s disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully…
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target…
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including…
Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate…
